Doug Drysdale

Doug Drysdale, Chief Executive Officer

  • An experienced Corporate Director and CEO: Doug has chaired the board of directors of a NASDAQ-listed company
    and as a CEO for the past 12 years has built and turned-around three pharmaceutical companies.

  • During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams,
    recruited board members, completed 15 corporate acquisitions across three continents and has raised $4
    billion of both public and private capital.

  • Led the turnaround of Norwich Pharmaceuticals alongside investors and became the Founding CEO of parent
    company, Alvogen Group. During his 5.5 year tenure as CEO, Alvogen grew from inception to $450 million
    in revenues across 35 countries.

  • In early 2014, Doug led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising $65
    million. Within the first year of taking the helm as Chairman and CEO, Doug rebuilt the management
    team and board of directors, combined several operating locations, and grew the company’s enterprise
    value from $80 million to around $800 million. Under Doug’s leadership, Pernix raised $465 million
    of capital.

  • From November 2017 to July 2020, Doug was a Director and CEO of Tedor Pharma, a family-owned
    contract manufacturing business. Doug’s efforts to turnaround the business resulted in 60%
    revenue growth in 2019, leading to Tedor being recognized as one of America’s fastest-growing
    companies, making it to the 2020 Inc 5000 list.

  • Former Head of M&A at Actavis Group, leading 15 corporate acquisitions across three
    continents, between 2004 and 2008, including a high-profile public hostile takeover attempt
    in Central Eastern Europe. Over this period, Doug raised approximately $3 billion of capital
    and managed lending syndicates including 25+ banks, to fund the company’s growth. Actavis
    was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion.

  • Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of
    East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and
    Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 45 countries,
    is an avid reader and enjoys cooking and boating.